Skip to main content
The Cochrane Database of Systematic Reviews logoLink to The Cochrane Database of Systematic Reviews
. 2017 Nov 1;2017(11):CD012850. doi: 10.1002/14651858.CD012850

Occlusal interventions for managing temporomandibular disorders

Balendra P Singh 1,✉, Srinivasan Jayaraman 2, Richard Kirubakaran 3, Suja Joseph 4, Murugan S Muthu 5, Hemant Jivnani 6, Fang Hua 7, Nishi Singh 8
PMCID: PMC6485535

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of occlusal interventions in people diagnosed with TMD, compared to other interventions or no treatment, for reduction in joint pain, muscle pain at rest and during mastication, quality of life, and discomfort.

Background

Description of the condition

Temporomandibular disorders (TMD) refer to impaired function of the temporomandibular joints (TMJ) and the associated neuromuscular system, which can provoke pain (Schiffman 2014). Other symptoms include limited jaw movement, TMJ noises, locking of TMJ, and headache (Schiffman 2014). Temporomandibular disorder pain has a negative effect on psychosocial functioning and quality of life, and is associated with anxiety and depression (List 2001; Bonjardim 2005; Hirsch 2010).

Three percent to 7% of the general population seek professional help for treatment of TMD annually (Carlsson 1999). The estimated worldwide prevalence of TMD varies greatly, from 5% to 23% (NIDCR 2016). This is due to non‐standardised diagnostic criteria, and age, gender, and population characteristics (Liu 2013; Da Silva 2016). The currently recommended diagnostic protocol is the new evidence‐based DC/TMD (Diagnostic Criteria for Temporomandiublar Disorders) for use in clinical and research settings, which is a revised version of RDC/TMD (Research Diagnostic Criteria for Temporomandibular Disorders) (Dworkin 1992). The DC/TMD criteria have a sensitivity of 70% or greater and specificity of 95% or greater (Schiffman 2014).

The aetiology of TMD was previously considered to be occlusal disharmonies or skeletal malalignments, but this mechanistic concept has been challenged and refuted in various studies (Posselt 1971; Jankelson 1979; Weinberg 1979; Suvinen 2005; Manfredini 2017). The aetiological concept is now based on a biopsychosocial model of pain, which suggests that pain is not a purely sensory process but has cognitive, emotional, and behavioural aspects. These aspects influence how people react to and report pain, as well as their choice of coping strategies, which can be helpful or harmful for maintaining function (Epker 1999; Turner 2005).

Description of the intervention

Interventions to treat or manage TMD include occlusal splints (reflex appliances, repositioning appliances, and stabilisation appliances), orthodontic therapy, occlusal adjustments, pharmacological treatment, physical treatment, behavioural therapy, acupuncture, surgical modalities, and multimodal treatment.

Occlusal splint is defined as any removable artificial occlusal surface affecting the relationship of the mandible to the maxillae used for diagnosis or therapy. Uses of this device may include, but are not limited to, occlusal stabilisation for the treatment of TMD, diagnostic overlay prior to extensive intervention, radiation therapy, occlusal positioning, and prevention of wear of the dentition or damage to brittle restorative materials such as dental porcelain (GPT‐9). Occlusal splint is classified into reflex appliances (e.g. Interceptor, anterior plateau, Nociceptive Trigeminal Inhibition tension suppression system (NTI‐tss), stabilisation appliances (Michigan splint), and repositioning appliances (e.g. anterior repositioning splint, Gelb type splint) (Freesmeyer 2005). It can be either in the maxillary arch or mandibular arch. Generally, two different materials are used in fabrication: hard acrylic resin, and soft or resilient plastics. Duration of oral appliance wear can vary from weeks to months, depending on symptoms (Dao 1998).

Orthodontic therapies, which include fixed orthodontic appliances (such as Damon appliance), removable orthodontic appliances and clear aligners, are used to treat malocclusions to prevent and treat TMD (Michelotti 2010; Schupp 2010; Koul 2012). Occlusal adjustments are done by selective grinding of the occlusal surface of teeth to equilibrate/correct occlusal interference, which causes orthopaedic instability of the TMJ and hyperactivity of muscles of mastication (Herb 2006; Torii 2010). Other physical, behavioural, and psychological therapies are used alone or as adjuvant therapy to treat TMD or alleviate pain (Suvinen 2005).

How the intervention might work

The change in the understanding of the aetiology of TMD from mechanistic concept to biopsychological model of pain has led to changes in the treatment of the condition. The most common intervention is still occlusal splint therapy (Wright 2009). Previous literature has proposed both dental and non‐dental reasons for its efficacy (Klasser 2009). Dental reasons include alteration of the occlusal condition, alteration of the condylar position, and increase in the vertical dimension of occlusion. Non‐dental reasons include cognitive awareness, placebo effect, increased peripheral input to the central nervous system leading to decreased motor activity, and regression to the mean (natural fluctuation of symptoms) (Okeson 2003). Reflex appliances prevent habitual tooth contact and so temporarily prevent clenching and gnashing, which may lead to improvement in TMD symptoms. Stabilisation appliance places the condyle in the centric position with freedom in centric and canine guidance. Repositioning appliances work by recapturing the disk to facilitate positioning of TMJ in therapeutic position to support healing and improve symptoms of TMJ disorder such as disk displacement with or without reduction (Tecco 2010).

Various orthodontics treatment such as fixed and removable appliances are tested to improve clinical symptoms of TMD. A few studies have found improvement in joint and muscle pain, but not in the treatment of joint noise (Tecco 2010; Nilsson 2011). It is proposed that, by treating malocclusion, orthodontic therapies can lead to the remodelling of TMJ, which overrides new functional needs and allows normal function to continue (Moss 1969).

Occlusal adjustment is selective adjustment of the occlusal surface of teeth by grinding the enamel so that the maxillary and mandibular teeth fit together (the intercuspal position) harmoniously, eliminating centric interferences. Occlusal adjustments can be made to ensure that when the lower jaw is moved to one side, the teeth on the other side do not touch (non‐working side contacts), removing working and non‐working side interferences, and that when the lower jaw moves forward, the back teeth do not touch, eliminating protrusive interferences (Shillingburg 2008). Another technique for occlusal adjustment is computer‐guided immediate complete anterior guidance development, which has shown some success in treating myofascial pain by decreasing disclusion time to less than 0.4 seconds each excursion (Kerstein 1992). Disclusion time is the time required by posterior teeth to disclude from each other during mandibular excursion. This decrease in disclusion time may reduce hyperactivity of muscle, thereby reducing chronic myofascial pain (Kerstein 1992; Kerstein 1993; Thumati 2014).

Why it is important to do this review

Temporomandibular disorders include a variety of conditions associated with pain and dysfunction of TMJ and the masticatory muscles. There is currently a lack of consensus among clinicians, researchers, and healthcare professionals regarding the management of these disorders. The selection of treatment is largely empirical, based on the skill and experience of the clinician. In addition, although limited research has been conducted to assess TMD‐associated expenditure, the estimated cost ranges from USD 12,000 to 20,000 annually per patient, depending on the insurance and use of direct or indirect cost variables (Brotman 1997).

The purpose of this review is to evaluate all occlusal interventions against other interventions for treating TMD so that stakeholders can make informed treatment decisions.

Objectives

To assess the effects of occlusal interventions in people diagnosed with TMD, compared to other interventions or no treatment, for reduction in joint pain, muscle pain at rest and during mastication, quality of life, and discomfort.

Methods

Criteria for considering studies for this review

Types of studies

We will include randomised controlled trials comparing occlusal interventions for TMD with any other active intervention, placebo, or no treatment. We will not include cross‐over data, as we cannot discount any period effects, and instead will use the first‐period data only and treat such studies as parallel studies. Duration of follow‐up should be at least one week. we will include studies in any language.

Types of participants

We will include all studies of people with TMD. We will use a broad definition of TMD, including those diagnosed according to published criteria RDC/TMD, Dworkin 1992, or DC/TMD criteria, Schiffman 2014, or future version (if any), or American Association of Orofacial Pain (AAOFP) guidelines (De Leeuw 2013). There will be no age restriction.

We will exclude trials involving people with congenital abnormalities, concomitant inflammatory or neoplastic conditions, a recent history of acute trauma or any form of therapy (including medication) within the preceding month, and people who are completely or partially edentulous with distal extension with or without prosthesis.

Types of interventions

The intervention of interest will be:

  • occlusal splints: reflex appliances, stabilisation appliances, or repositioning appliances;

  • orthodontic therapy;

  • occlusal adjustment.

Comparisons may include:

  • no treatment or placebo (i.e. inactive appliance) or waiting‐list control;

  • occlusal splint of different materials/design/arch coverage of same classification (reflex or repositioning or stabilisation splint), e.g. soft Michigan splint versus hard Michigan splint;

  • other types of active treatments (e.g. physical therapy, behavioural therapy (psychological), acupuncture, pharmacological therapy, etc.).

Types of outcome measures

Primary outcomes
  1. Reduction in joint pain both at rest and mastication, which may be self reported or clinically assessed

  2. Reduction in muscle pain both at rest and mastication

  3. Participant satisfaction or quality of life

  4. Any adverse effect or discomfort

Secondary outcomes
  1. Severity, frequency of joint noises

  2. Range of mandibular motion

  3. Duration of treatment

  4. Recurrence rate

  5. Depression

  6. Somatisation

We will categorise outcomes according to follow‐up time as short term (three months or less) or long term (more than three months).

Search methods for identification of studies

Cochrane Oral Health’s Information Specialist will conduct systematic searches for randomised controlled trials and controlled clinical trials. Due to the Cochrane Embase Project to identify all clinical trials on the database and add them to CENTRAL, only recent months of the Embase database will be searched. Please see the searching page on the Cochrane Oral Health website for more information. No other restrictions will be placed on the language or date of publication when searching the electronic databases.

Electronic searches

We will search the following databases for relevant trials:

  • Cochrane Oral Health's Trials Register;

  • the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Register of Studies;

  • MEDLINE Ovid (from 1946 onwards);

  • Embase Ovid (previous six months to date, with updates as required).

The subject strategies for databases will be modelled on the search strategy designed for MEDLINE Ovid in Appendix 1. Where appropriate, this will be combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials (as described in theCochrane Handbook for Systematic Reviews of Interventions) (Lefebvre 2011).

Searching other resources

The following trials registries will be searched:

  • US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/);

  • World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch).

We will check the bibliographies of included studies and any relevant systematic reviews identified for further references to relevant trials. We will not perform a separate search for adverse effects of interventions, and will consider only adverse effects described in studies included in the review.

Data collection and analysis

Selection of studies

We will import all of the search records into reference manager software and check for duplicate publications. We will link multiple reports of the same study. Two review authors (BPS, SJ) will independently read and judge all titles and abstracts for possible inclusion in the review. In case of discrepancy, we will consult a third review author (HJ) for clarification. If studies of a review author are identified in the search results, other review authors who were not involved in the study will assess eligibility. We will obtain full texts of the selected studies, and two review authors (BPS, SJ) will read them for inclusion or exclusion in the review. Two review authors (HJ, RK) will resolve any discrepancies. If uncertainties remain or further information is required, we will contact the corresponding author. If this fails, we will discuss all uncertainties in the review. We will record excluded studies and reasons for their exclusion in the 'Characteristics of excluded studies' table.

Data extraction and management

We will conduct data extraction from the studies according to the guidance of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), using a data extraction form containing the information below. Two review authors (BPS, SJ) will independently extract data, with any disagreements being resolved by RK and then HJ.

  • Study eligibility verification: we will conduct a pilot test to verify eligibility criteria by considering one study in each criteria as definitely eligible, definitely not eligible, and doubtful, based on inclusion and exclusion criteria, interventions, comparators, and outcomes.

  • General details: study ID, author details, title, journal name, year, volume and page number, publisher, funding source, name of review author who will perform data extraction, clinical trial registry number.

  • Study methods: inclusion and exclusion criteria, study design, ethical approval detail, randomisation method, allocation concealment method, blinding method and types, start and end date of trial, study duration, follow‐up length, conflict of interest, other possible biases.

  • Population characteristics: age, gender, marital status, race, employment status, referral type, education, research setting, recruitment methods, type of TMD, signs and symptoms, presence or absence of assessment and reporting of psychological factors (e.g. anxiety, depression, catastrophisation), treatment received in the past with reference to current disease, withdrawal and exclusion, total number in each group, and other details.

  • Interventions:

    • oral appliances: name and type of oral appliance, site of wear, area of tooth structures covered by the appliance, occlusal surface, occlusion, softness, wearing time, materials used, any fabrication methods, and other details;

    • orthodontic therapy: type, duration, design, materials used, follow‐up, wearing time, and other details; and

    • occlusal adjustments, pharmacological, physical treatment, behavioural therapy, surgical modalities: type, duration, session detail, session location (home or health centre), total duration of intervention, experience level of administrator, dose, follow‐up, route of administration, site or muscles involved in intervention, and other details.

    • We will record habituation period for cross‐over trials.

  • Outcomes: primary and secondary outcomes, including time points of assessment and follow‐up.

Assessment of risk of bias in included studies

Two review authors (BPS, SJ) will independently assess the risk of bias of all included studies for the following domains according to the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). SJ or HJ will check all 'Risk of bias' assessments. Any disagreements will be resolved by consensus amongst review authors.

  1. Random sequence generation (selection bias)

  2. Allocation concealment (selection bias)

  3. Blinding of participants and personnel (performance bias)

  4. Blinding of outcome assessment (detection bias)

  5. Incomplete outcome assessment (attrition bias)

  6. Selective outcome reporting bias (reporting bias)

  7. Other bias

We will grade the risk of bias as low, high, or unclear based on the preset criteria presented below and generate a 'Risk of bias' graph to illustrate the proportion of studies with each grade for each 'Risk of bias' domain. We will prepare a 'Risk of bias' summary figure presenting all of the judgements in a cross‐tabulation of study by entry. When necessary, we will contact authors for clarification regarding bias. If we receive no response from the author and the methods mentioned in an article are unclear, we will consider that study to be at unclear risk of bias.

Risk of bias Interpretation Within a study Across studies
Low risk of bias Plausible bias that is unlikely to seriously alter the results Low risk of bias for all key domains Most information is from studies at low risk of bias.
Unclear risk of bias Plausible bias that raises some doubt about the results Unclear risk of bias for one or more key domains Most information is from studies at low or unclear risk of bias.
High risk of bias Plausible bias that seriously weakens confidence in the results High risk of bias for one or more key domains The proportion of information from studies at high risk of bias is sufficient to affect the interpretation of the results.

Measures of treatment effect

For dichotomous data, we will report the risk ratio (RR) with 95% confidence interval (CI) as the effect estimate. For continuous data, we will use mean difference (MD) and 95% CI to summarise the data. If different studies measure outcomes using different scales, we will use standardised mean difference (SMD) with 95% CI.

Unit of analysis issues

We will use the participant as the unit of analysis and follow the guidelines in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). To prevent a unit of analysis error with cross‐over trials, we will use first‐period data only and consider the study as a parallel‐group trial in our analyses.

Dealing with missing data

We will contact authors to obtain any missing data. We will estimate missing data from the available data using the methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

Assessment of heterogeneity

We will assess three types of heterogeneity, that is clinical, methodological, and statistical, as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will include gender, age, type and severity of TMD, occlusion, other participant characteristics, follow‐up, outcomes measured, bias, and other factors in clinical and methodological heterogeneity. We will check statistical heterogeneity by magnitude, direction of effects, and strength of evidence for heterogeneity (P value from the Chi2 test, or a confidence interval for I2). A P value less than 0.1 will indicate statistically significant heterogeneity. We will use I2 to quantify heterogeneity according to Higgins 2011. We will present the I2 statistic as a percentage, with a rough guide for interpretation is as follows:

  • 0% to 40% might not be important;

  • 30% to 60% may represent moderate heterogeneity;

  • 50% to 90% may represent substantial heterogeneity;

  • 75% to 100% represents very substantial ('considerable') heterogeneity.

When I2 is more than 60%, we will investigate heterogeneity using a random‐effects model or explore it using a subgroup analysis.

Assessment of reporting biases

If we find a sufficient number of studies (at least 10), we will attempt to assess publication bias using a funnel plot as described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).

Data synthesis

We will conduct data analysis in Review Manager 5 using methods described in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011; Review Manager 2014). We will perform meta‐analyses if we find homogeneity across participants, interventions, and outcomes. We will combine MDs or SMDs for continuous data, and RRs for dichotomous data. If we find significant heterogeneity, we will use a random‐effects model because the confidence interval will be wider, representing a more conservative approach than the fixed‐effect model. If we find limited information (e.g. few studies or studies with small sample size), we will provide data in an additional table and in narrative format.

Subgroup analysis and investigation of heterogeneity

We will perform subgroup analyses for:

  • diagnostic method used;

  • participant characteristics such as age and gender; and

  • different techniques to measure participant symptoms.

Sensitivity analysis

If meta‐analyses include several small studies and a single very large study, we will undertake a sensitivity analysis comparing the effect estimates from both random‐effects and fixed‐effect models. If these are different, we will report both analyses in the Results section of the review, and consider possible interpretation. To test the robustness of the pooled estimate of effects, we will carry out a sensitivity analysis by excluding studies with unclear and high risk of bias. We will undertake a sensitivity analysis restricted to trials where the inclusion criteria are based on, or can be clearly mapped to, one of the following sets of diagnostic criteria:

Presentation of main results

We will use GRADEpro software to create 'Summary of findings' tables in accordance with the section 11.5 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), employing GRADE methods (GRADE 2004; GRADEpro GDT 2015). We will summarise and evaluate the following outcomes for quality of evidence: reduction in joint pain, muscle pain, discomfort, joint noises, and recurrence rate. Since we are including randomised controlled trials, the body of evidence begins as high quality and will be downgraded if indicated based on the following domains: study limitation (risk of bias), inconsistency, indirectness, imprecision, and publication bias. We will evaluate the quality of evidence as high, moderate, low, or very low, providing an appropriate justification.

Acknowledgements

The review authors would like to acknowledge the contribution of Laura MacDonald and Anne Littlewood at Cochrane Oral Health. We thank Helen Worthington, Anne‐Marie Glenny, Phil Riley, Giovanni Lodi and external referees Justin Durham and Robert Jagger for their comments, and Lisa Winer for final copy editing. Balendra Pratap Singh would like to acknowledge the scientific content support for this review given by Prof Pooran Chand.

Appendices

Appendix 1. MEDLINE Ovid search strategy

1. exp Craniomandibular disorders/ 2. Facial pain/ 3. Facial neuralgia/ 4. Trigeminal neuralgia/ 5. Arthralgia/ and temporomandibular joint/ 6. (temporomandibular or temporo‐mandibular or craniomandibular or cranio mandibular).mp. 7. exp myofascial pain syndromes/ 8. (myofascial and (pain or disorder$ or dysfunction$)).mp. 9. (tmj or tmd or cmd or cmj).ti,ab. 10. ((mandib$ or jaw or facial or orofacial) adj3 (pain$ or ((disc or disk) and (displac$ or derang$)))).mp. 11. exp bruxism/ 12. (bruxism or (teeth adj5 grind$) or (teeth adj5 clench) or (jaw$ adj5 clench) or (jaw$ adj5 grind$)).mp. 13. ("trigeminal neuralgia" or "sphenopalatine neuralgia" or "Costen$ syndrome$").mp. 14. or/1‐13 15. Occlusal adjustment/ 16. Orthodontics/ 17. Mandibular advancement/ 18. Occlusal splints/ 19. (occlus$ adj5 adjust$).mp. 20. orthodontic$.mp. 21. ("nociceptive trigeminal inhibition tension suppression system" or NTI‐TSS).mp. 22. ((oral or occlusal) adj5 appliance$).mp. 23. (splint$ or stent$ or "bite guard$").mp. 24. ((dental or mouth or gum) adj (guard$ or shield$)).mp. 25. (mouthguard$ or gumguard$ or nightguard$ or gumshield$ or "bite plane$" or toothprotector$ or "tooth protector$").mp. 26. or/15‐23 27. 14 and 26

This search will be combined with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised trials in MEDLINE: sensitivity‐maximising version (2008 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of The Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] (Lefebvre 2011).

1. randomized controlled trial.pt. 2. controlled clinical trial.pt. 3. randomized.ab. 4. placebo.ab. 5. drug therapy.fs. 6. randomly.ab. 7. trial.ab. 8. groups.ab. 9. or/1‐8 10. exp animals/ not humans.sh. 11. 9 not 10

Contributions of authors

Conception and design of study Balendra Pratap Singh
Drafting the review or commenting on it critically for intellectual content Balendra Pratap Singh, Srinivasan Jayaraman, Suja Joseph, Murugan S Muthu, Fang Hua
Analysis and interpretation of data Richard Kirubakaran, Balendra Pratap Singh, Hemant Jivanani
Final approval of the document to be published Balendra Pratap Singh, Srinivasan Jayaraman, Suja Joseph, Nishi Singh

Sources of support

Internal sources

  • Balendra Pratap Singh, India.

    • Author is receiving salary, IT, library support and travel support to attend 'Protocol Development Workshop' at CMC, Vellore from King George's Medical University, Lucknow, India.

External sources

  • Cochrane Oral Health Global Alliance, Other.

    The production of Cochrane Oral Health reviews has been supported financially by our Global Alliance since 2011 (ohg.cochrane.org/partnerships‐alliances). Contributors over the past year have been: British Association for the Study of Community Dentistry, UK; British Society of Paediatric Dentistry, UK; the Canadian Dental Hygienists Association, Canada; Centre for Dental Education and Research at All India Institute of Medical Sciences, India; National Center for Dental Hygiene Research & Practice, USA; New York University College of Dentistry, USA; NHS Education for Scotland, UK; Swiss Society for Endondontology, Switzerland.

  • National Institute for Health Research (NIHR), UK.

    This project was supported by the NIHR, via Cochrane Infrastructure funding to Cochrane Oral Health. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health.

Declarations of interest

Balendra Pratap Singh: none known Srinivasan Jayaraman: none known Richard Kirubakaran: none known Suja Joseph: none known Murugan S Muthu: none known Hemant Jivanani: none known Fang Hua: none known Nishi Singh: none known

New

References

Additional references

  1. Bonjardim LR, Gavião MB, Pereira LJ, Castelo PM. Anxiety and depression in adolescents and their relationship with signs and symptoms of temporomandibular disorders. International Journal of Prosthodontics 2005;18(4):347‐52. [PubMed] [Google Scholar]
  2. Brotman SG. Managed health care and orofacial pain. Dental Clinics of North America 1997;41(2):297‐307. [PubMed] [Google Scholar]
  3. Carlsson GE. Epidemiology and treatment need for temporomandibular disorders. Journal of Orofacial Pain 1999;13(4):232‐7. [PubMed] [Google Scholar]
  4. Silva CG, Pachêco‐Pereira C, Porporatti AL, Savi MG, Peres MA, Flores‐MirC, et al. Prevalence of clinical signs of intra‐articular temporomandibular disorders in children and adolescents: a systematic review and meta‐analysis. Journal of the American Dental Association 1999;147(1):10‐18.e8. [DOI] [PubMed] [Google Scholar]
  5. Dao TT, Lavigne GJ. Oral splints: the crutches for temporomandibular disorders and bruxism?. Critical Reviews in Oral Biology and Medicine 1998;9(3):345‐61. [DOI] [PubMed] [Google Scholar]
  6. Leeuw R, Klasser GD, American Academy of Orofacial Pain. Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. 5th Edition. Chicago: Quintessence Publishing Company, Inc, 2013. [Google Scholar]
  7. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: review, criteria, examinations and specifications, critique. Journal of Craniomandibular Disorders 1992;6(4):301‐55. [PubMed] [Google Scholar]
  8. Epker J, Gatchel RJ, Ellis E 3rd. A model for predicting chronic TMD: practical application in clinical settings. Journal of the American Dental Association 1999;130(10):1470‐5. [DOI] [PubMed] [Google Scholar]
  9. Freesmeyer WB, Fussnegger MR, Ahlers MO. Diagnostic and therapeutic‐restorative procedures for masticatory dysfunctions. GMS Current Topics in Otorhinolaryngology, Head and Neck Surgery 2005;4(Doc19). [PMC free article] [PubMed] [Google Scholar]
  10. The Glossary of Prosthodontic Terms. Journal of Prosthetic Dentistry 2017;117(5):e1‐105. [DOI] [PubMed] [Google Scholar]
  11. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 1 April 2017. Hamilton, ON: McMaster University (developed by Evidence Prime), 2015. Available at www.gradepro.org.
  13. Herb K, Cho S, Stiles MA. Temporomandibular joint pain and dysfunction. Current Pain and Headache Reports 2006;10(6):408‐14. [DOI] [PubMed] [Google Scholar]
  14. Higgins JPT, Green S, (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
  15. Hirsch C, Türp JC. Temporomandibular pain and depression in adolescents ‐ a case‐control study. Clinical Oral Investigations 2010;14(2):145‐51. [DOI] [PubMed] [Google Scholar]
  16. Jankelson B. Neuromuscular aspects of occlusion. Effects of occlusal position on the physiology and dysfunction of the mandibular musculature. Dental Clinics of North America 1979;23(2):157‐68. [PubMed] [Google Scholar]
  17. Kerstein R. Disclusion time reduction therapy with immediate complete anterior guidance development: the technique. Quintessence International 1992;23:735‐47. [PubMed] [Google Scholar]
  18. Kerstein RB. A comparison of traditional occlusal equilibration and immediate complete anterior guidance development. Cranio: the Journal of Craniomandibular Practice 1993;11:126‐39. [DOI] [PubMed] [Google Scholar]
  19. Klasser GD, Greene CS. Oral appliances in the management of temporomandibular disorders. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2009;107(2):212‐23. [DOI] [PubMed] [Google Scholar]
  20. Koul R. Orthodontic implications of growth and differently enabled mandibular movements for the temporomandibular joint. Seminars in Orthodontics 2012;18:73‐91. [Google Scholar]
  21. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
  22. List T, Wahlund K, Larsson B. Psychosocial functioning and dental factors in adolescents with temporomandibular disorders: a case‐control study. Journal of Orofacial Pain 2001;15(3):218‐27. [PubMed] [Google Scholar]
  23. Liu F, Steinkeler A. Epidemiology, diagnosis, and treatment of temporomandibular disorders. Dental Clinics of North America 2013;57(3):465‐79. [DOI] [PubMed] [Google Scholar]
  24. Manfredini D, Lombardo L, Siciliani G. Temporomandibular disorders and dental occlusion. A systematic review of association studies: end of an era?. Journal of Oral Rehabilitation 2017;44(11):908‐23. [DOI: 10.1111/joor.12531] [DOI] [PubMed] [Google Scholar]
  25. Michelotti A, Iodice G. The role of orthodontics in temporomandibular disorders. Journal of Oral Rehabilitation 2010;37(6):411‐29. [DOI] [PubMed] [Google Scholar]
  26. Moss ML, Salentijn L. The primary role of functional matrices in facial growth. American Journal of Orthodontics 1969;55(6):566‐77. [DOI] [PubMed] [Google Scholar]
  27. National Institute of Dental and Craniofacial Research. Facial pain. www.nidcr.nih.gov/DataStatistics/FindDataByTopic/FacialPain/ (accessed 12 September 2016).
  28. Nilsson H, Vallon D, Ekberg EC. Long‐term efficacy of resilient appliance therapy in TMD pain patients: a randomised, controlled trial. Journal of Oral Rehabilitation 2011;38(10):713‐21. [DOI] [PubMed] [Google Scholar]
  29. Okeson JP. Occlusal appliance therapy. Managment of Temporomandibular Disorders and Occlusion. 5th Edition. St. Louis: Mosby, 2003:532‐3. [Google Scholar]
  30. Posselt U. The temporomandibular joint syndrome and occlusion. Journal of Prosthetic Dentistry 1971;25(4):432‐8. [DOI] [PubMed] [Google Scholar]
  31. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
  32. Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD Consortium Network and Orofacial Pain Special Interest Group. Journal of Oral & Facial Pain and Headache 2014;28:6–27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schupp W, Haubrich J, Neumann I. Invisalign(®) treatment of patients with craniomandibular disorders. International Orthodontics 2010;8:253‐67. [DOI] [PubMed] [Google Scholar]
  34. Shillingburg HT. Cementation and bonding. Fundamentals of Fixed Prosthodontics. 4th Edition. Quintessence Publishing Co, Inc, 2008:393‐7. [Google Scholar]
  35. Suvinen TI, Reade PC, Kemppainen P, Könönen M, Dworkin SF. Review of aetiological concepts of temporomandibular pain disorders: towards a biopsychosocial model for integration of physical disorder factors with psychological and psychosocial illness impact factors. European Journal of Pain (London, England) 2005;9(6):613‐33. [DOI] [PubMed] [Google Scholar]
  36. Tecco S, Teté S, Crincoli V, Festa MA, Festa F. Fixed orthodontic therapy in temporomandibular disorder (TMD) treatment: an alternative to intraoral splint. Cranio: the Journal of Craniomandibular Practice 2010;28(1):30‐42. [DOI] [PubMed] [Google Scholar]
  37. Thumati P, Manwani R, Mahantshetty M. The effect of reduced disclusion time in the treatment of myofacial pain dysfunction syndrome using immediate complete anterior guidance development protocol monitored by digital analysis of occlusion. Journal of Craniomandibular & Sleep Practice 2014;32:289‐99. [DOI] [PubMed] [Google Scholar]
  38. Torii K, Chiwata I. Occlusal adjustment using the bite plate‐induced occlusal position as a reference position for temporomandibular disorders: a pilot study. Head & Face Medicine 2010;27(6):5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Turner JA, Brister H, Huggins K, Mancl L, Aaron LA, Truelove EL. Catastrophizing is associated with clinical examination findings, activity interference, and health care use among patients with temporomandibular disorders. Journal of Orofacial Pain 2005;19(4):291‐300. [PubMed] [Google Scholar]
  40. Weinberg LA. Role of condylar position in TMJ dysfunction‐pain syndrome. Journal of Prosthetic Dentistry 1979;41(6):636‐43. [DOI] [PubMed] [Google Scholar]
  41. Wright EF, North SL. Management and treatment of temporomandibular disorders: a clinical perspective. Journal of Manual & Manipulative Therapy 2009;17(4):247‐54. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Cochrane Database of Systematic Reviews are provided here courtesy of Wiley

RESOURCES